SEC Form 4 · accession 0001214659-18-005912
NEXIEN BIOPHARMA, INC. · NXEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alain D Bankier
Officer — Chief Executive Officer · Director
Period of report
Aug 6, 2018
Accepted (ET)
Sep 5, 2018 · 12:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001625288
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 2,256,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class C Warrants (right to buy)F4 | $0.50 | Aug 6, 2018 | J | 28,000 | D | Nov 29, 2017 | Aug 8, 2018 | Common Stock | 28,000 | 0 | D |
| Class D Warrants (right to buy)F4,F3 | $1.00 | Aug 6, 2018 | J | 28,000 | A | Aug 6, 2018 | Sep 28, 2018 | Units | 28,000 | 28,000 | D |
| Stock option - right to buyF1 | $0.54 | holding | — | — | — | Jul 25, 2018 | Jul 25, 2023 | Common Stock | 840,000 | 840,000 | D |
| Stock option - right to buyF2 | $0.54 | holding | — | — | — | Jul 25, 2018 | Jul 25, 2023 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F170,000 options vested immediately, with the remainder vesting monthly over the next 11 months beginning August 1, 2018.
- F225,000 options vested immediately, with the remainder vesting quarterly over the next 6 quarters beginning with the quarter ending September 30, 2018.
- F3Each unit consists of one share of common stock and one Class E Warrant.
- F4Class C Warrants were exchanged for an equal number of Class D Warrants.